Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
TQB-2223 by Chia Tai Tianqing Pharmaceutical Group for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
TQB-2223 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Bile Duct Cancer...